Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Growth Inhibitory Activity of Indian Terminalia spp. against the Zoonotic Bacterium Bacillus anthracis

    wadmin2By wadmin2December 1, 2015Updated:August 11, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Mitchell Henry Wright,1 Reece Courtney,1,2 Anthony Carlson Greene,1 Ian Edwin Cock,1,2*
    1School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA.
    2Environmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland 4111, AUSTRALIA.

    Pharmacognosy Communications,2016,6,1,2-9.
    DOI:10.5530/pc.2016.1.2
    Published: December 2015
    Type: Original Article

    ABSTRACT

    Introduction: Anthrax is a zoonotic disease caused by the soil bacterium Bacillus anthracis. It has an extremely high mortality rate if untreated. Terminalia spp. have a long association with the treatment of various ailments, including bacterial infections although they have not been tested for the ability to inhibit the growth of B. anthracis. Methods: Solvent extracts were prepared using Terminalia spp. known to inhibit microorganism growth. The antibacterial potential of the extracts were investigated by disc diffusion assay to determine the growth inhibitory potential against an environmental strain of B. anthracis. Their MIC values were calculated to quantify and compare their relative efficacies. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Extracts prepared from several Indian Terminalia spp. displayed potent antibacterial activity in the disc diffusion assay against B. anthracis. The methanolic T. chebula fruit extract was particularly effective at inhibiting microbial growth, with MIC values against B. anthracis of 166 μg/mL (<2 μg impregnated in the disc). The aqueous T. chebula extract, as well as T. catappa and T. arjuna methanolic extracts, were also good growth inhibitors with MIC’s generally <2500 μg/mL (<25 μg impregnated in the disc). All other plant extracts were either inactive or of only low inhibitory activity. None of the extracts were deemed toxic, with all recorded LC50 values substantially>1000 μg/mL. Conclusion: The potent growth inhibitory activity of the methanolic T. chebula fruit extract against B. anthracis indicates its potential in the treatment and prevention of anthrax. Furthermore, due to its low toxicity, its use may extend to all forms of the disease (cutaneous, inhalation or gastrointestinal) and may extend to live stock as well as humans. 

    Key words: Terminalia, Antibacterial activity, Terminalia chebula, Terminalia catappa, Terminalia arjuna, Anthrax, Traditional medicine.
    Download PDF

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up